Literature DB >> 30529845

3D-QSAR assisted identification of FABP4 inhibitors: An effective scaffold hopping analysis/QSAR evaluation.

Giuseppe Floresta1, Agostino Cilibrizzi2, Vincenzo Abbate3, Ambra Spampinato4, Chiara Zagni4, Antonio Rescifina5.   

Abstract

Following on the recent publication of pharmacologically relevant effects, small molecule inhibitors of adipocyte fatty-acid binding protein 4 (FABP4) have attracted high interest. FABP4 is mainly expressed in macrophages and adipose tissue, where it regulates fatty acid storage and lipolysis, being also an important mediator of inflammation. In this regard, FABP4 recently demonstrated an interesting molecular target for the treatment of type 2 diabetes, other metabolic diseases and some type of cancers. In the past years, hundreds of effective FABP4 inhibitors have been synthesized. In this paper, a quantitative structure-activity relationship (QSAR) model has been produced, in order to predict the bioactivity of FABP4 inhibitors. The methodology has been combined with a scaffold-hopping approach, allowing to identify three new molecules that act as effective inhibitors of this protein. These molecules, synthesized and tested for their FABP4 inhibitor activity, showed IC50 values between 3.70 and 5.59 μM, with a high level of agreement with the predicted values.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3D-QSAR; A-FABP; BMS309403 analogs; FABP4 inhibitors; Forge and Spark software; Scaffold-hopping; Thiazole; Triazole; aP2

Mesh:

Substances:

Year:  2018        PMID: 30529845     DOI: 10.1016/j.bioorg.2018.11.045

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  8 in total

1.  Effects of the histone acetylase inhibitor C646 on growth and differentiation of adipose-derived stem cells.

Authors:  Zhimin Wang; Xiao Wang; Meiyu Bi; Xiao Hu; Qing Wang; Hao Liang; Dongjun Liu
Journal:  Cell Cycle       Date:  2021-01-25       Impact factor: 4.534

2.  Repurposing strategies on pyridazinone-based series by pharmacophore- and structure-driven screening.

Authors:  Giuseppe Floresta; Letizia Crocetti; Maria Paola Giovannoni; Pierfrancesco Biagini; Agostino Cilibrizzi
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

3.  Computational Tools in the Discovery of FABP4 Ligands: A Statistical and Molecular Modeling Approach.

Authors:  Giuseppe Floresta; Davide Gentile; Giancarlo Perrini; Vincenzo Patamia; Antonio Rescifina
Journal:  Mar Drugs       Date:  2019-10-31       Impact factor: 5.118

4.  An Integrated Pharmacophore/Docking/3D-QSAR Approach to Screening a Large Library of Products in Search of Future Botulinum Neurotoxin A Inhibitors.

Authors:  Davide Gentile; Giuseppe Floresta; Vincenzo Patamia; Rita Chiaramonte; Giulia Letizia Mauro; Antonio Rescifina; Michele Vecchio
Journal:  Int J Mol Sci       Date:  2020-12-12       Impact factor: 5.923

Review 5.  Structural derivatization strategies of natural phenols by semi-synthesis and total-synthesis.

Authors:  Ding Lin; Senze Jiang; Ailian Zhang; Tong Wu; Yongchang Qian; Qingsong Shao
Journal:  Nat Prod Bioprospect       Date:  2022-03-07

6.  Machine learning vs. field 3D-QSAR models for serotonin 2A receptor psychoactive substances identification.

Authors:  Giuseppe Floresta; Vincenzo Abbate
Journal:  RSC Adv       Date:  2021-04-20       Impact factor: 3.361

7.  Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with Potent In Vitro Antiproliferative Activity.

Authors:  Antonino N Fallica; Valeria Sorrenti; Agata G D'Amico; Loredana Salerno; Giuseppe Romeo; Sebastiano Intagliata; Valeria Consoli; Giuseppe Floresta; Antonio Rescifina; Velia D'Agata; Luca Vanella; Valeria Pittalà
Journal:  J Med Chem       Date:  2021-09-02       Impact factor: 7.446

Review 8.  Artificial Intelligence Technologies for COVID-19 De Novo Drug Design.

Authors:  Giuseppe Floresta; Chiara Zagni; Davide Gentile; Vincenzo Patamia; Antonio Rescifina
Journal:  Int J Mol Sci       Date:  2022-03-17       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.